Literature DB >> 11953401

Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3.

Scott Shapiro1, David O Beenhouwer, Marta Feldmesser, Carlos Taborda, Michael C Carroll, Arturo Casadevall, Matthew D Scharff.   

Abstract

Passive administration of monoclonal antibodies (MAbs) to the capsular polysaccharide of Cryptococcus neoformans can alter the course of infection in mice. In a murine model of cryptococcal infection, immunoglobulin G1 (IgG1), IgG2a, and IgG2b switch variants of the anti-capsular 3E5 MAb prolong the survival of lethally infected mice, whereas the 3E5 IgG3 MAb does not protect and in some cases enhances infection, shortening the life spans of infected mice. We examined the role of complement component C3 in Ab-mediated protection by determining the efficacy of the four mouse IgG subclasses against C. neoformans in mice genetically deficient in factor C3 as well as mice acutely depleted of C3. Similar to other complement-deficient animal models, C3(-/-) mice and mice depleted of C3 by cobra venom factor were more susceptible to C. neoformans infection than control mice, providing further evidence that complement is important in the host defense against the fungus. In the absence of C3, all IgG isotypes prolonged the lives of mice infected with C. neoformans, indicating that protection by IgG does not require the complement pathways. Furthermore, we observed protection with IgG3 in the complement-deficient mice, suggesting that complement is involved in the lack of protection observed with IgG3 in other mouse models.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11953401      PMCID: PMC127925          DOI: 10.1128/IAI.70.5.2598-2604.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  58 in total

1.  Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins.

Authors:  T R Kozel; M A Wilson; G S Pfrommer; A M Schlageter
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

2.  Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide.

Authors:  J E Sanford; D M Lupan; A M Schlageter; T R Kozel
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

3.  Role of IgG and complement component C5 in the initial course of experimental cryptococcosis.

Authors:  F Dromer; C Perronne; J Barge; J L Vilde; P Yeni
Journal:  Clin Exp Immunol       Date:  1989-12       Impact factor: 4.330

Review 4.  Overview of host defenses in fungal infections.

Authors:  S M Levitz
Journal:  Clin Infect Dis       Date:  1992-03       Impact factor: 9.079

5.  Enhancement of HIV-1 infection by the capsular polysaccharide of Cryptococcus neoformans.

Authors:  M Pettoello-Mantovani; A Casadevall; T R Kollmann; A Rubinstein; H Goldstein
Journal:  Lancet       Date:  1992-01-04       Impact factor: 79.321

6.  Deficiency of the murine fifth complement component (C5). A 2-base pair gene deletion in a 5'-exon.

Authors:  R A Wetsel; D T Fleischer; D L Haviland
Journal:  J Biol Chem       Date:  1990-02-15       Impact factor: 5.157

7.  Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice.

Authors:  S Mukherjee; S Lee; J Mukherjee; M D Scharff; A Casadevall
Journal:  Infect Immun       Date:  1994-03       Impact factor: 3.441

8.  Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans.

Authors:  T R Kozel; M A Wilson; J W Murphy
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

9.  The capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibody.

Authors:  R M Syme; T F Bruno; T R Kozel; C H Mody
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

10.  The fifth component of complement (C5) in the mouse. Analysis of the molecular basis for deficiency.

Authors:  W H Wheat; R Wetsel; A Falus; B F Tack; R C Strunk
Journal:  J Exp Med       Date:  1987-05-01       Impact factor: 14.307

View more
  42 in total

Review 1.  New concepts in antibody-mediated immunity.

Authors:  Arturo Casadevall; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

2.  Of mice and men, revisited: new insights into an ancient molecule from studies of complement activation by Cryptococcus neoformans.

Authors:  Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

3.  Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection.

Authors:  David O Beenhouwer; Esther M Yoo; Chun-Wei Lai; Miguel A Rocha; Sherie L Morrison
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

Review 4.  Antibody-mediated protection through cross-reactivity introduces a fungal heresy into immunological dogma.

Authors:  Arturo Casadevall; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2007-08-20       Impact factor: 3.441

5.  Complement and Fc function are required for optimal antibody prophylaxis against Pneumocystis carinii pneumonia.

Authors:  Jesse Wells; Constantine G Haidaris; Terry W Wright; Francis Gigliotti
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

6.  In vitro C3 deposition on Cryptococcus capsule occurs via multiple complement activation pathways.

Authors:  Kileen L Mershon-Shier; Alex Vasuthasawat; Kazue Takahashi; Sherie L Morrison; David O Beenhouwer
Journal:  Mol Immunol       Date:  2011-07-01       Impact factor: 4.407

7.  Yersinia pseudotuberculosis uses Ail and YadA to circumvent neutrophils by directing Yop translocation during lung infection.

Authors:  Michelle K Paczosa; Michael L Fisher; Francisco J Maldonado-Arocho; Joan Mecsas
Journal:  Cell Microbiol       Date:  2013-11-03       Impact factor: 3.715

8.  The monoclonal antibody against the major diagnostic antigen of Paracoccidioides brasiliensis mediates immune protection in infected BALB/c mice challenged intratracheally with the fungus.

Authors:  R Buissa-Filho; R Puccia; A F Marques; F A Pinto; J E Muñoz; J D Nosanchuk; L R Travassos; C P Taborda
Journal:  Infect Immun       Date:  2008-05-05       Impact factor: 3.441

9.  O antigen protects Bordetella parapertussis from complement.

Authors:  Elizabeth M Goebel; Daniel N Wolfe; Kelly Elder; Scott Stibitz; Eric T Harvill
Journal:  Infect Immun       Date:  2008-02-19       Impact factor: 3.441

10.  Bordetella pertussis infection or vaccination substantially protects mice against B. bronchiseptica infection.

Authors:  Elizabeth M Goebel; Xuqing Zhang; Eric T Harvill
Journal:  PLoS One       Date:  2009-08-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.